What is the appropriate evaluation for a patient with elevated prothrombin time, international normalized ratio, and activated partial thromboplastin time?

Evaluation of Elevated PT, INR, and PTT

When a patient presents with elevated PT, INR, and PTT, immediately assess for anticoagulant exposure (warfarin, heparin, or direct oral anticoagulants), obtain a detailed medication history including timing of last dose, and perform targeted laboratory testing based on the suspected anticoagulant to determine if levels are clinically relevant and guide reversal if bleeding is present. 1

Initial Clinical Assessment

Determine Anticoagulant Exposure

• Document all anticoagulant medications including warfarin (vitamin K antagonists), unfractionated heparin, low-molecular-weight heparin, and direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) 1
• Record timing of last dose as this critically affects interpretation of coagulation tests and drug levels 1
• Assess bleeding status: Identify if patient has active bleeding (minor, moderate, or life-threatening), bleeding at critical sites, or is asymptomatic 1
• Evaluate hemodynamic stability: Check blood pressure, pulse, and signs of volume depletion 1

Essential Laboratory Tests

Beyond PT/INR and aPTT, obtain:

• Complete blood count with hemoglobin, hematocrit, and platelet count 1
• Renal function (creatinine clearance) as this affects drug metabolism, particularly for dabigatran 1
• Hepatic function as liver disease affects both coagulation factor synthesis and drug metabolism 1

Anticoagulant-Specific Evaluation

For Warfarin (Vitamin K Antagonist)

• PT/INR is the validated test for assessing warfarin effect 1
• INR is only valid for patients on warfarin and should not be used to assess coagulopathy in other contexts (liver disease, trauma, non-VKA anticoagulants) 1
• Document modifiable bleeding risk factors: uncontrolled hypertension, concomitant antiplatelet/NSAID use, excessive alcohol intake, poor INR control (time in therapeutic range <65%) 1
• aPTT may be mildly prolonged but is not the primary monitoring test 1

For Dabigatran (Direct Thrombin Inhibitor)

• Thrombin time (TT): A normal TT excludes clinically relevant dabigatran levels 1
• aPTT: Prolonged aPTT suggests on-therapy or above on-therapy levels, but normal aPTT does not exclude therapeutic levels, especially with insensitive reagents 1
• PT/INR are mildly elevated but less sensitive than aPTT for dabigatran 1
• Diluted thrombin time (dTT) or ecarin chromogenic assay (ECA) provide quantitative dabigatran concentrations if available 1
• Clinically relevant levels: Consider reversal for serious bleeding if dabigatran level >50 ng/mL 1

For Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban)

• Anti-Factor Xa assay (calibrated for specific drug): Below lower limit of quantitation probably excludes clinically relevant levels 1
• PT prolongation: Rivaroxaban and edoxaban prolong PT in dose-dependent manner, but sensitivity varies by reagent; apixaban may not prolong PT at therapeutic concentrations 1
• Do NOT interpret PT as INR in patients on direct oral anticoagulants—INR is invalid in this context 1
• aPTT: Less sensitive than PT for Factor Xa inhibitors; normal aPTT does not exclude therapeutic levels 1
• Clinically relevant levels: Consider reversal for serious bleeding if DOAC level >50 ng/mL, or >30 ng/mL for high bleeding risk procedures 1

For Heparin

• aPTT is the primary monitoring test for unfractionated heparin (target 1.5-2.5 times control or 45-75 seconds) 1
• PT/INR may be mildly prolonged but are not primary monitoring tests 1
• Anti-Factor Xa assay can be used for low-molecular-weight heparin monitoring when needed 1

Special Considerations

Liver Disease

• INR is NOT valid for assessing coagulopathy in liver disease—it was designed only for warfarin monitoring 1
• Modified INR-liver has been proposed but not widely implemented 1
• PT expressed as activity percentage may be more appropriate than INR in liver failure 2, 3
• Elevated PT/INR does not predict bleeding risk in cirrhotic patients undergoing procedures 1

Trauma and Critical Illness

• INR poorly predicts bleeding risk in trauma, acute illness, and perioperative settings when not on warfarin 1
• Common coagulation assays may show prolongation in trauma patients on DOACs, but normal values do not exclude drug effect 1

Critical Pitfalls to Avoid

• Do not use INR to assess coagulopathy in patients not on warfarin—it lacks validity and can lead to inappropriate plasma transfusion 1
• Do not assume normal PT/aPTT excludes therapeutic DOAC levels, particularly for apixaban and edoxaban 1
• Do not transfuse plasma based solely on elevated INR in non-bleeding patients—there is no evidence of benefit and definite harm 1
• Reagent sensitivity varies significantly: PT/aPTT results depend heavily on specific reagents and coagulometers used 1, 4, 3